Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Veracyte, Inc. develops molecular tests for oncology. The Company offers molecular cytology and tests for the diagnostic accuracy of cytology samples. Veracyte provides its products and services to healthcare and molecular diagnostic companies in the United States.
Website: veracyte.com


  • Good financial results growth rate 34.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (10.2%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 2.2% (LTM)
  • Share price is 121.0% higher than minimum and 15.6% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (64.3x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $6.4 mln (-0.185% of cap.)

Key Financials (Download financials)

Ticker: VCYT
Share price, USD:  (+0.3%)41.69
year average price 34.11  


year start price 43.60 2025-01-21

min close price 23.03 2025-07-21

max close price 49.38 2025-11-25

current price 41.69 2026-01-21
Common stocks: 78 725 139

Dividend Yield:  0.0%
FCF Yield LTM: 2.2%
EV / LTM EBITDA: 64.3x
EV / EBITDA annualized: 26.4x
Last revenue growth (y/y):  +13.8%
Last growth of EBITDA (y/y):  +55.6%
Historical revenue growth:  +20.4%
Historical growth of EBITDA:  0.0%
EV / Sales: 6.0x
Margin (EBITDA LTM / Revenue): 9.3%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 3 282
Net Debt ($m): -326
EV (Enterprise Value): 2 956
EBITDA LTM (млн $): 46
EV / LTM EBITDA: 64.3x
Price to Book: 2.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-16seekingalpha.com

Veracyte: Profitable, De-Risked, And Ready To Run

2026-01-15seekingalpha.com

Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-29businesswire.com

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

2025-12-23zacks.com

Is This the Right Time to Add Veracyte Stock to Your Portfolio?

2025-12-02zacks.com

Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term

2025-11-11zacks.com

VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up

2025-11-04seekingalpha.com

Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript

2025-10-15businesswire.com

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

2025-10-07zacks.com

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

2025-09-29zacks.com

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-07 2024-05-08 2024-02-29 2023-11-08 2023-08-09 2023-05-05 2023-03-01 2022-11-03
acceptedDate 2025-11-05 08:15:57 2025-08-07 16:41:08 2024-11-07 08:01:01 2024-08-07 08:11:25 2024-05-08 17:03:22 2024-02-29 08:06:41 2023-11-08 08:30:57 2023-08-09 16:07:39 2023-05-05 08:07:27 2023-02-28 17:48:53 2022-11-03 07:57:44
calendarYear 2025 2025 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
revenue 132M 130M 116M 114M 97M 98M 90M 90M 82M 80M 76M
costOfRevenue 43M 40M 37M 39M 36M 35M 28M 30M 26M 27M 26M
grossProfit 89M 90M 79M 76M 61M 63M 62M 61M 56M 53M 50M
grossProfitRatio 0.678 0.69 0.682 0.662 0.625 0.643 0.694 0.671 0.682 0.666 0.656
researchAndDevelopmentExpenses 16M 16M 18M 16M 16M 18M 13M 13M 13M 11M 11M
generalAndAdministrativeExpenses 0 14M 26M 48M 43M 41M 16M 25M 22M 18M 18M
sellingAndMarketingExpenses 0 43M 23M 7M 6M 7M 24M 26M 26M 24M 26M
sellingGeneralAndAdministrativeExpenses 51M 57M 48M 55M 49M 46M 41M 51M 49M 42M 43M
otherExpenses 0 22M 0 -125 000 43 000 355 000 40M -226 000 5M 5M 5M
operatingExpenses 66M 95M 66M 71M 65M 65M 94M 69M 67M 59M 59M
costAndExpenses 109M 135M 103M 110M 101M 100M 122M 98M 93M 86M 85M
interestIncome 3M 3M 3M 3M 3M 3M 2M 1M 1M -824 000 573 000
interestExpense 0 0 1000 1000 0 2000 2000 3000 7000 -192 000 61 000
depreciationAndAmortization 5M 5M 6M 6M 6M 6M 7M 7M 7M 7M 6M
ebitda 24M 7M 23M 11M 1M 5M 45M -1M -4M 1M -3M
ebitdaratio 0.183 0.052 0.196 0.091 0.014 0.05 0.504 -0.013 -0.046 0.014 -0.044
operatingIncome 23M -5M 12M 5M -4M -1M -32M -8M -10M -5M -10M
operatingIncomeRatio 0.175 -0.04 0.104 0.041 -0.044 -0.015 -0.352 -0.089 -0.127 -0.067 -0.128
totalOtherIncomeExpensesNet -4M 7M 5M 3M 2M -29M 2M -226 000 2M 2M 805 000
incomeBeforeTax 19M 1M 17M 7M -2M -30M -30M -8M -8M -3M -9M
incomeBeforeTaxRatio 0.143 0.01 0.145 0.064 -0.02 -0.31 -0.33 -0.092 -0.098 -0.043 -0.117
incomeTaxExpense -248 000 2M 2M 2M -44 000 -2M -154 000 125 000 -2M 403 000 -152 000
netIncome 19M -980 000 15M 6M -2M -28M -30M -8M -6M -4M -9M
netIncomeRatio 0.145 -0.008 0.131 0.05 -0.019 -0.288 -0.329 -0.093 -0.069 -0.048 -0.115
eps 0.243 -0.013 0.2 0.075 -0.025 -0.39 -0.41 -0.12 -0.079 -0.054 -0.12
epsdiluted 0.24 -0.013 0.19 0.074 -0.025 -0.39 -0.41 -0.12 -0.079 -0.054 -0.12
weightedAverageShsOut 79M 78M 77M 77M 75M 73M 73M 72M 72M 72M 72M
weightedAverageShsOutDil 80M 80M 78M 77M 75M 73M 73M 72M 72M 72M 72M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-07 2024-05-08 2024-02-29 2023-11-08 2023-08-09 2023-05-05 2023-03-01 2022-11-03
acceptedDate 2025-11-05 08:15:57 2025-08-07 16:41:08 2024-11-07 08:01:01 2024-08-07 08:11:25 2024-05-08 17:03:22 2024-02-29 08:06:41 2023-11-08 08:30:57 2023-08-09 16:07:39 2023-05-05 08:07:27 2023-02-28 17:48:53 2022-11-03 07:57:44
calendarYear 2025 2025 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
cashAndCashEquivalents 316M 219M 274M 236M 209M 216M 202M 191M 178M 154M 170M
shortTermInvestments 51M 101M 0 0 0 0 0 0 0 25M 0
cashAndShortTermInvestments 366M 321M 274M 236M 209M 216M 202M 191M 178M 179M 170M
netReceivables 48M 51M 49M 50M 47M 45M 39M 42M 45M 44M 40M
inventory 20M 25M 20M 19M 18M 16M 16M 12M 13M 14M 14M
otherCurrentAssets 15M 18M 14M 16M 16M 8M 14M 14M 15M 11M 15M
totalCurrentAssets 449M 415M 357M 321M 290M 286M 271M 259M 252M 249M 239M
propertyPlantEquipmentNet 56M 57M 38M 40M 33M 31M 31M 31M 29M 31M 31M
goodwill 767M 773M 762M 752M 754M 703M 693M 699M 700M 696M 677M
intangibleAssets 92M 96M 109M 113M 116M 89M 124M 165M 170M 175M 177M
goodwillAndIntangibleAssets 860M 869M 871M 865M 870M 792M 817M 864M 870M 871M 853M
longTermInvestments 2M 0 0 1M 1M 876 000 870 000 0 0 0 0
taxAssets 0 0 0 0 1 23M -870 000 0 0 0 0
otherNonCurrentAssets 1M 3M 9M 7M 6M 6M 6M 7M 6M 6M 3M
totalNonCurrentAssets 919M 929M 918M 913M 910M 852M 854M 902M 906M 908M 887M
otherAssets 0 0 0 0 0 1 0 0 0 0 0
totalAssets 1 368M 1 344M 1 275M 1 234M 1 200M 1 138M 1 125M 1 161M 1 157M 1 156M 1 126M
accountPayables 6M 11M 10M 12M 12M 13M 13M 13M 16M 12M 11M
shortTermDebt 4M 6M 7M 14M 6M 5M 5M 5M 4M 4M 5M
taxPayables 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 417 000 1M 2M 2M 3M 2M 2M 2M 2M 3M 4M
otherCurrentLiabilities 62M 57M 51M 44M 37M 41M 38M 38M 34M 44M 38M
totalCurrentLiabilities 72M 76M 70M 72M 58M 61M 57M 58M 56M 63M 58M
longTermDebt 36M 44M 12M 14M 8M 8M 9M 10M 10M 11M 12M
deferredRevenueNonCurrent 0 0 0 0 0 -1 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 1M 1M 1M 1M 1M 24M 4M 5M 5M 5M 4M
otherNonCurrentLiabilities 583 000 1M 15M 14M 14M 1M 1M 6M 6M 3M -694 000
totalNonCurrentLiabilities 38M 47M 29M 29M 23M 32M 14M 20M 20M 19M 19M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0
capitalLeaseObligations 36M 51M 20M 21M 8M 8M 14M 15M 14M 15M 15M
totalLiabilities 110M 123M 99M 102M 81M 94M 71M 78M 76M 81M 78M
preferredStock 0 0 0 0 499M 0 474M 438M 0 0 0
commonStock 79 000 79 000 77 000 77 000 76 000 73 000 73 000 73 000 72 000 72 000 72 000
retainedEarnings -419M -438M -449M -464M -470M -468M -440M -410M -402M -394M -390M
accumulatedOtherComprehensiveIncomeLoss -8M -12M -21M -31M -29M -24M -34M -28M -27M -31M -54M
othertotalStockholdersEquity 1 685M 1 671M 1 646M 1 627M 1 119M 1 536M 1 054M 1 083M 1 510M 1 500M 1 492M
totalStockholdersEquity 1 258M 1 221M 1 176M 1 133M 1 119M 1 044M 1 054M 1 083M 1 081M 1 075M 1 048M
totalEquity 1 258M 1 221M 1 176M 1 133M 1 119M 1 044M 1 054M 1 083M 1 081M 1 075M 1 048M
totalLiabilitiesAndStockholdersEquity 1 368M 1 344M 1 275M 1 234M 1 200M 1 138M 1 125M 1 161M 1 157M 1 156M 1 126M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 368M 1 344M 1 275M 1 234M 1 200M 1 138M 1 125M 1 161M 1 157M 1 156M 1 126M
totalInvestments 52M 101M 0 1M 1M 876 000 870 000 0 0 25M 0
totalDebt 40M 51M 20M 21M 14M 13M 14M 15M 14M 15M 17M
netDebt -275M -169M -254M -215M -195M -204M -189M -176M -164M -140M -153M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-07 2024-05-08 2024-02-29 2023-11-08 2023-08-09 2023-05-05 2023-03-01 2022-11-03
acceptedDate 2025-11-05 08:15:57 2025-08-07 16:41:08 2024-11-07 08:01:01 2024-08-07 08:11:25 2024-05-08 17:03:22 2024-02-29 08:06:41 2023-11-08 08:30:57 2023-08-09 16:07:39 2023-05-05 08:07:27 2023-02-28 17:48:53 2022-11-03 07:57:44
calendarYear 2025 2025 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q4 Q3
netIncome 19M -980 000 15M 6M -2M -28M -30M -8M -8M -4M -9M
depreciationAndAmortization 5M 5M 6M 6M 6M 6M 7M 7M 7M 7M 6M
deferredIncomeTax -87 000 59 000 -13 000 143 000 -120 000 -3M -968 000 125 000 0 403 000 -152 000
stockBasedCompensation 11M 11M 9M 10M 8M 8M 7M 10M 8M 7M 7M
changeInWorkingCapital 6M 1M 17M 6M -23M 1M -2M 6M -10M -398 000 504 000
accountsReceivables 425 000 3M 2M -4M -6M -763 000 3M 3M -1M 5M -1M
inventory 221 000 -565 000 -909 000 -963 000 -2M -58 000 -4M 2M 1M -170 000 813 000
accountsPayables -4M -4M -1M -162 000 -2M -319 000 -607 000 -1M 2M 477 000 1M
otherWorkingCapital 9M 3M 17M 11M -13M 3M 614 000 3M -2M -6M 63 000
otherNonCashItems 3M 17M -17M 28M 32M 32M 32M 1M 2M 160 000 2M
netCashProvidedByOperatingActivities 45M 34M 30M 30M -9M 16M 14M 17M -2M 10M 7M
investmentsInPropertyPlantAndEquipment -3M -1M -2M -3M -2M -2M -3M -4M -993 000 -2M -2M
acquisitionsNet 0 0 0 0 5M 25M 0 0 0 0 0
purchasesOfInvestments 0 -50M 0 0 0 0 0 0 -20M -25M 0
salesMaturitiesOfInvestments 51M 0 0 0 0 0 0 0 45M -15 000 11M
otherInvestingActivites 0 51M 0 0 0 -25M 0 0 0 0 0
netCashUsedForInvestingActivites 48M -224 000 -2M -3M 3M -2M -3M -4M 24M -26M 9M
debtRepayment 0 0 0 0 0 -4M 0 0 0 -1M -3000
commonStockIssued 6M 0 -4M 1M 3M 2M 3M 0 4M 8M 0
commonStockRepurchased 0 0 5M -1M -4M -1M -2M 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -3M -566 000 10M -11 000 -4M 3M -2M 397 000 -2M -7M 1M
netCashUsedProvidedByFinancingActivities 3M -566 000 10M -11 000 -864 000 645 000 110 000 397 000 2M 93 000 1M
effectOfForexChangesOnCash 77 000 573 000 146 000 -61 000 -108 000 297 000 -177 000 -7000 50 000 732 000 -654 000
netChangeInCash 96M 33M 39M 27M -7M 14M 11M 13M 24M -16M 17M
cashAtEndOfPeriod 316M 221M 275M 236M 209M 216M 203M 192M 179M 155M 171M
cashAtBeginningOfPeriod 219M 188M 237M 209M 216M 202M 192M 179M 155M 171M 154M
operatingCashFlow 45M 34M 30M 30M -9M 16M 14M 17M -2M 10M 7M
capitalExpenditure -3M -1M -2M -3M -2M -2M -3M -4M -993 000 -2M -2M
freeCashFlow 42M 32M 28M 27M -11M 13M 11M 13M -3M 8M 5M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-24 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-04 16:08 ET
Veracyte published news for 2025 q3
SEC form 8
2025-11-04 16:08 ET
Veracyte reported for 2025 q3
SEC form 10
2025-08-07 20:41 ET
Veracyte reported for 2025 q2
SEC form 8
2025-08-06 20:08 ET
Veracyte published news for 2025 q2
SEC form 8
2025-08-06 20:08 ET
Veracyte published news for 2025 q2
SEC form 10
2025-05-08 12:06 ET
Veracyte published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Veracyte published news for 2025 q1
SEC form 8
2025-05-07 20:07 ET
Veracyte published news for 2025 q1
SEC form 8
2025-05-07 20:07 ET
Veracyte reported for 2025 q1
SEC form 10
2025-02-28 02:58 ET
Veracyte published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Veracyte published news for 2024 q4
SEC form 8
2025-02-24 16:11 ET
Veracyte published news for 2024 q4
SEC form 8
2025-02-24 16:11 ET
Veracyte reported for 2024 q4
SEC form 10
2024-11-07 08:01 ET
Veracyte published news for 2024 q3
SEC form 8
2024-11-06 16:11 ET
Veracyte published news for 2024 q3
SEC form 8
2024-11-06 16:11 ET
Veracyte published news for 2024 q3
SEC form 10
2024-08-07 08:11 ET
Veracyte published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Veracyte published news for 2024 q2
SEC form 8
2024-08-06 16:16 ET
Veracyte published news for 2024 q2
SEC form 8
2024-08-06 16:16 ET
Veracyte reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Veracyte published news for 2024 q1
SEC form 8
2024-05-07 16:10 ET
Veracyte published news for 2024 q1
SEC form 8
2024-05-07 16:10 ET
Veracyte reported for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Veracyte published news for 2023 q4
SEC form 8
2024-02-22 16:12 ET
Veracyte published news for 2023 q4
SEC form 8
2024-02-22 16:12 ET
Veracyte reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Veracyte published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Veracyte published news for 2023 q4
SEC form 10
2023-11-08 08:30 ET
Veracyte published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Veracyte published news for 2023 q3
SEC form 8
2023-11-07 16:09 ET
Veracyte reported for 2023 q3
SEC form 10
2023-08-09 16:07 ET
Veracyte published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Veracyte published news for 2023 q2
SEC form 6
2023-08-08 16:11 ET
Veracyte reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Veracyte published news for 2023 q2
SEC form 6
2023-06-09 17:01 ET
Veracyte published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Veracyte published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Veracyte published news for 2023 q1
SEC form 10
2023-03-01 00:00 ET
Veracyte reported for 2022 q4
SEC form 10
2023-02-28 17:48 ET
Veracyte reported for 2022 q4
SEC form 6
2023-02-22 16:08 ET
Veracyte published news for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Veracyte reported for 2022 q4
SEC form 6
2023-02-10 16:44 ET
Veracyte published news for 2022 q4
SEC form 6
2022-12-14 08:25 ET
Veracyte published news for 2022 q3
SEC form 10
2022-11-03 07:57 ET
Veracyte reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Veracyte reported for 2022 q3
SEC form 6
2022-11-02 16:11 ET
Veracyte published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Veracyte reported for 2022 q3
SEC form 6
2022-09-07 16:56 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-11 16:26 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-11 16:24 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-09 17:19 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-09 17:17 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-09 17:16 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-09 17:16 ET
Veracyte published news for 2022 q2
SEC form 10
2022-08-03 08:01 ET
Veracyte reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Veracyte reported for 2022 q2
SEC form 6
2022-08-02 16:15 ET
Veracyte published news for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Veracyte reported for 2022 q2
SEC form 6
2022-06-16 20:12 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:12 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:12 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:11 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:06 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:04 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 16:15 ET
Veracyte published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Veracyte reported for 2022 q1
SEC form 10
2022-05-03 17:57 ET
Veracyte reported for 2022 q1
SEC form 6
2022-05-03 16:12 ET
Veracyte published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Veracyte reported for 2022 q1
SEC form 6
2022-04-26 16:14 ET
Veracyte published news for 2022 q1
SEC form 6
2022-03-03 20:27 ET
Veracyte published news for 2021 q4
SEC form 10
2022-02-28 16:40 ET
Veracyte published news for 2021 q4
SEC form 6
2022-02-28 16:11 ET
Veracyte published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Veracyte published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Veracyte published news for 2021 q4
SEC form 6
2022-02-22 16:40 ET
Veracyte published news for 2021 q4
SEC form 6
2022-01-13 16:47 ET
Veracyte published news for 2021 q4
SEC form 6
2022-01-11 16:50 ET
Veracyte published news for 2021 q4
SEC form 10
2021-11-09 16:37 ET
Veracyte published news for 2021 q3
SEC form 6
2021-11-09 16:11 ET
Veracyte published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Veracyte published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Veracyte published news for 2021 q3
SEC form 6
2021-08-04 16:14 ET
Veracyte published news for 2021 q2
SEC form 6
2021-08-03 08:09 ET
Veracyte published news for 2021 q2
SEC form 10
2021-07-29 16:19 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-29 16:16 ET
Veracyte published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Veracyte published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-20 16:44 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-16 09:02 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-13 16:58 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-12 08:37 ET
Veracyte published news for 2021 q2
SEC form 6
2021-06-10 16:21 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:20 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:18 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:16 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:12 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:11 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-08 16:40 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-08 16:38 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-08 16:35 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-03 17:00 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-01 07:16 ET
Veracyte published news for 2021 q1
SEC form 6
2021-05-19 17:16 ET
Veracyte published news for 2021 q1
SEC form 10
2021-05-10 16:23 ET
Veracyte published news for 2021 q1
SEC form 6
2021-05-10 16:17 ET
Veracyte published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Veracyte published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Veracyte published news for 2021 q1
SEC form 6
2021-04-23 16:12 ET
Veracyte published news for 2021 q1
SEC form 6
2021-04-15 16:55 ET
Veracyte published news for 2021 q1
SEC form 8
2021-04-15 00:00 ET
Veracyte published news for 2021 q1
SEC form 6
2021-04-05 16:58 ET
Veracyte published news for 2021 q1
SEC form 6
2021-04-05 16:50 ET
Veracyte published news for 2021 q1
SEC form 6
2021-03-23 16:38 ET
Veracyte published news for 2020 q4
SEC form 6
2021-03-22 09:21 ET
Veracyte published news for 2020 q4
SEC form 6
2021-03-15 16:23 ET
Veracyte published news for 2020 q4
SEC form 6
2021-03-03 16:07 ET
Veracyte published news for 2020 q4
SEC form 10
2021-02-22 16:18 ET
Veracyte published news for 2020 q4
SEC form 6
2021-02-17 16:17 ET
Veracyte published news for 2020 q4
SEC form 6
2021-02-05 06:17 ET
Veracyte published news for 2020 q4
SEC form 6
2021-02-03 08:21 ET
Veracyte published news for 2020 q4
SEC form 6
2021-01-25 08:33 ET
Veracyte published news for 2020 q4
SEC form 6
2020-12-16 17:14 ET
Veracyte published news for 2020 q3
SEC form 6
2020-11-17 16:39 ET
Veracyte published news for 2020 q3
SEC form 10
2020-11-02 16:20 ET
Veracyte published news for 2020 q3
SEC form 6
2020-11-02 16:15 ET
Veracyte published news for 2020 q3